{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Labots M"],"funding":["Vitromics Healthcare Services"],"pagination":["E330"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC7072422"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["12(2)"],"pubmed_abstract":["Identification of predictive biomarkers for targeted therapies requires information on drug exposure at the target site as well as its effect on the signaling context of a tumor. To obtain more insight in the clinical mechanism of action of protein kinase inhibitors (PKIs), we studied tumor drug concentrations of protein kinase inhibitors (PKIs) and their effect on the tyrosine-(pTyr)-phosphoproteome in patients with advanced cancer. Tumor biopsies were obtained from 31 patients with advanced cancer before and after 2 weeks of treatment with sorafenib (SOR), erlotinib (ERL), dasatinib (DAS), vemurafenib (VEM), sunitinib (SUN) or everolimus (EVE). Tumor concentrations were determined by LC-MS/MS. pTyr-phosphoproteomics was performed by pTyr-immunoprecipitation followed by LC-MS/MS. Median t"],"journal":["Cancers"],"pubmed_title":["Kinase Inhibitor Treatment of Patients with Advanced Cancer Results in High Tumor Drug Concentrations and in Specific Alterations of the Tumor Phosphoproteome."],"pmcid":["PMC7072422"],"funding_grant_id":["N/A"],"pubmed_authors":["Meijerink MR","van Grieken NCT","de Goeij-de Haas R","Neerincx M","Labots M","Pham TV","Knol JC","Honeywell RJ","van der Peet DL","Piersma SR","Verheul HMW","Dekker H","Beekhof R","van der Mijn JC","Peters GJ","Jimenez CR"],"additional_accession":[]},"is_claimable":false,"name":"Kinase Inhibitor Treatment of Patients with Advanced Cancer Results in High Tumor Drug Concentrations and in Specific Alterations of the Tumor Phosphoproteome.","description":"Identification of predictive biomarkers for targeted therapies requires information on drug exposure at the target site as well as its effect on the signaling context of a tumor. To obtain more insight in the clinical mechanism of action of protein kinase inhibitors (PKIs), we studied tumor drug concentrations of protein kinase inhibitors (PKIs) and their effect on the tyrosine-(pTyr)-phosphoproteome in patients with advanced cancer. Tumor biopsies were obtained from 31 patients with advanced cancer before and after 2 weeks of treatment with sorafenib (SOR), erlotinib (ERL), dasatinib (DAS), vemurafenib (VEM), sunitinib (SUN) or everolimus (EVE). Tumor concentrations were determined by LC-MS/MS. pTyr-phosphoproteomics was performed by pTyr-immunoprecipitation followed by LC-MS/MS. Median t","dates":{"release":"2020-01-01T00:00:00Z","publication":"2020 Feb","modification":"2026-04-08T02:08:11.599Z","creation":"2020-05-22T13:28:56Z"},"accession":"S-EPMC7072422","cross_references":{"pubmed":["32024067"],"doi":["10.3390/cancers12020330"]}}